15 completed, 3 unknown, 2 active not recruiting, 2 recruiting. 28 Phase 2, 7 Phase 1, 3 Phase 3.
Follow Rejection, Psychology: new trials by email Literature Review of Rejection, Psychology trials Research Report on Rejection, Psychology
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| (TNX-1500) in Kidney Transplant Recipients TNX-1500, Kidney Transplant - Kidney Transplant, Kidney Transplant Failure and Rejection | Phase 2 | Not yet recruiting | Ayman Al Jurdi, MD | 5 | 2026-11-01 | 2026-08-19 |
| A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant Siplizumab, Rabbit anti-thymocyte globulin - Renal Transplant Failure and Rejection | Phase 2 | Recruiting | Nefro Avillion Clinical Development, LLC | 120 | 2026-06-29 | 2026-11-03 |
| Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection | Phase 2 / Phase 3 | Recruiting | Columbia University | 150 | 2025-09-12 | 2026-10-02 |
| Impact of SGLT2 Inhibitors in Heart Transplant Recipients SGLT2i - Transplant; Failure, Heart, Cardiac Allograft Vasculopathy | Phase 2 | Unknown | Universidade Federal do Ceara | 80 | 2023-11-20 | 2024-05-07 |
| Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Fingolimod, Placebo - Interstitial Fibrosis, Kidney Transplant; Complications | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 20 | 2022-07-28 | 2025-03-14 |
| Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY) Tacrolimus, Placebo - Organ Transplant Failure or Rejection, Brain Death | Phase 2 | Active not recruiting | Université de Sherbrooke | 414 | 2022-07-11 | 2025-04-17 |
| Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients QEL-001 - Rejection; Transplant, Liver, Liver Failure | Phase 1 / Phase 2 | Active not recruiting | Quell Therapeutics Limited | 33 | 2022-01-21 | 2026-07-02 |
| Selective CD28 Blockade in Renal Transplant Recipients Lulizumab, Tacrolimus, Thymoglobulin® - Kidney Transplantation, Renal Transplant Recipients | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-01-10 | 2023-03-22 | |
| Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation adipose derived mesenchymal stromal cells, Saline - Lung Transplant Rejection | Phase 1 / Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 30 | 2020-10-01 | 2021-07-16 |
| A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant Belatacept, VIB4920, Thymoglobulin - Allografts, Rejection; Transplant, Kidney | Phase 2 | Completed | Amgen | 25 | 2019-10-30 | 2024-12-27 |
| Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients immediate-release tacrolimus, extended release tacrolimus - Kidney Transplant Failure and Rejection | Phase 1 / Phase 2 | Completed | University of Minnesota | 18 | 2018-05-08 | 2021-04-15 |
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 20 | 2018-02-27 | 2026-10-30 |
| Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Eculizumab, Immunoglobulin, Plasmapheresis - Antibody-mediated Rejection, Humoral Rejection | Phase 2 | Terminated | Brigham and Women's Hospital | 11 | 2013-11-01 | 2017-09-21 |
| Acetaminophen and Social Processes Acetaminophen - Borderline Personality Disorder | Phase 2 | Completed | Ohio State University | 9 | 2013-09-01 | 2024-06-04 |
| Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury eculizumab - End-Stage Renal Disease, Kidney Failure | Phase 2 | Completed | Russian Academy of Medical Sciences | 57 | 2012-09-01 | 2018-08-31 |
| Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK) Prednisolone acetate, Fluorometholone - Fuchs' Dystrophy, Bullous Keratopathy | Phase 2 | Completed | Price Vision Group | 264 | 2011-10-01 | 2014-09-03 |
| Donor Simvastatin Treatment in Organ Transplantation Simvastatin 80mg, Control Rx - Heart Failure, Respiratory Failure | Phase 2 / Phase 3 | Completed | Helsinki University Central Hospital | 84 | 2010-06-01 | 2017-09-19 |
| Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells Efalizumab - Autoimmune Diseases | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2008-12-01 | 2013-05-14 | |
| 24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients AEB071, mycophenolic plus tacrolimus - Kidney Transplantation | Phase 2 | Terminated | Novartis Pharmaceuticals | 137 | 2007-10-01 | 2020-12-17 |
| Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation Alemtuzumab - Evidence of Liver Transplantation, Rejection | Phase 2 | Completed | University of Pittsburgh | 23 | 2007-04-01 | 2023-03-08 |
Showing 20 of 28. Sign in to see all of them.
Liver Diseases (4) · Kidney Failure, Chronic (3) · Renal Insufficiency (3) · Liver Failure (2) · Autoimmune Diseases (1) · Borderline Personality Disorder (1) · Brain Death (1) · Corneal dystrophy, Fuchs' endothelial, 1 (1) · Fibrosis (1) · Heart Failure (1) · Hepatitis (1) · Hepatitis C (1) · Hepatitis C, Chronic (1) · Infections (1)
Behavior (28) · Social Behavior (28) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Digestive System Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Chronic Disease (4) · Disease Attributes (4) · Renal Insufficiency, Chronic (3) · Hepatic Insufficiency (2)
Tacrolimus (6) · Mycophenolic Acid (5) · Adrenal Cortex Hormones (4) · thymoglobulin (4) · Antilymphocyte Serum (3) · sotrastaurin (3) · Abatacept (2) · Alemtuzumab (2) · Cyclosporine (2) · Fingolimod Hydrochloride (2) · Liver Transplantation (2) · Methylprednisolone (2) · Prednisone (2) · eculizumab (2) · Acetaminophen (1)
Novartis Pharmaceuticals (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Amgen (1) · Ayman Al Jurdi, MD (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Columbia University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Genzyme, a Sanofi Company (1) · Helsinki University Central Hospital (1) · Hunter and New England Health (1) · Nefro Avillion Clinical Development, LLC (1) · Ohio State University (1) · Price Vision Group (1) · Quell Therapeutics Limited (1)
United States (20) · Canada (6) · Spain (5) · Germany (4) · United Kingdom (4) · Belgium (2) · Brazil (2) · France (2) · Italy (2) · Switzerland (2) · Australia (1) · Denmark (1) · Finland (1) · Russia (1) · Sweden (1)
Abraham Shaked, MD, PhD (1) · Andrew B. Adams, MD, PhD (1) · Anil K Chandraker, MD (1) · Ayman Al Jurdi, MD (1) · Baldwin M Way, Ph.D. (1) · Christian P. Larsen, MD, DPhil (1) · Flavio Vincenti, M.D. (1) · Francis W Price, MD (1) · Friedrich Kruse, MD (1) · J. Richard Thistlethwaite, MD (1) · Jennifer S. Cheavens, Ph.D. (1) · Jens Kastrup, MD Professor (1)
PMID 14668458, PMID 14961990, PMID 17564637, PMID 17984842, PMID 21564523, PMID 25062336, PMID 30506630, PMID 31352795, PMID 33979314, PMID 37322595, PMID 38871657, PMID 40247997
KL2RR025754-04 (1), U01AI138909 (1)